ArticleAnnals of surgical oncology2026
Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplete macroscopic tumor resection is the strongest prognostic factor in advanced epithelial tubo-ovarian and primary peritoneal cancer, yet benefit from maximum-effort cytoreductive surgery may vary with tumor distribution and site-specific resections. We aimed to identify predictors of long-term survival, considering postoperative morbidity, to inform preoperative stratification. PATIENTS AND
methodsThis study had a retrospective single-center cohort of 302 all-comers patients with International Federation of Gynecology and Obstetrics/American Joint Committee on Cancer (FIGO/AJCC) IIIC-IV epithelial tubo-ovarian or primary peritoneal cancer undergoing maximum-effort cytoreductive surgery in a European Society of Gynecological Oncology (ESGO)-certified high-volume tertiary referral center (2006-2021). Major complications (Clavien-Dindo ≥ IIIb) were analyzed using multivariable logistic regression; progression-free and overall survival (PFS/OS) using Cox regression. Subgroup analyses explored site-specific bowel resections.
resultsComplete resection was achieved in 259 (85.8%) patients, requiring high surgical complexity in 221 (73.2%, Surgical Complexity Score ≥ 8). Intestinal segment resections were performed in 71.5% of patients, including ileocecal resection in 24.5%. Large bowel resection (OR 2.708, p = 0.002) significantly increased major postoperative morbidity. Anastomotic leakage occurred in 6.0%, independent of transitory stoma formation (p = 0.759). Small bowel resection independently predicted impaired long-term survival (3-year OS 31.8% versus 57.0%, p < 0.001). Ileocecal resections were associated with poorest outcome (3-year OS 24.2%, p < 0.001). Complete macroscopic resection remained prognostically beneficial. Neoadjuvant chemotherapy (13.9%) and high surgical complexity did not negatively affect long-term survival.
conclusionsIleocecal and small bowel involvement are independently associated with inferior survival despite complete cytoreduction in FIGO IIIC-IV disease. These findings support preoperative triage and counseling by the multidisciplinary tumor board, with selective consideration of primary systemic therapy with planned interval cytoreduction for extensive small bowel/ileocecal disease, particularly in frail or complex patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.